Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease
Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease
复制标题
DOI：
10.4049/jimmunol.164.10.5015
复制
发表时间：
2000-05-15
影响因子：
4.4
通讯作者：
Hallett, KM
中科院分区：
文献类型：
--
作者：
Oaks, MK;Hallett, KM
我们最近鉴定了 CTLA-4 基因的一种新转录本，它可能代表 CTLA-4 的天然可溶形式 (sCTLA-4)。为了确定 sCTLA-4 是否在人类中表达，我们对自身免疫性甲状腺疾病 (ATD) 患者的血清应用了灵敏的酶免疫测定法。20 名 ATD 患者中，有 11 名具有 sCTLA-4 的循环水平 范围为 28 至 78 ng/ml，而 30 名表面健康的志愿者中只有 1 人的水平高于 4 ng/ml。 sCTLA-4 的免疫反应性因与 B7.1 的结合而受到抑制，表明 sCTLA-4 是一种功能性受体。对 ATD 患者血清进行免疫沉淀分析，结果显示存在与 sCTLA-4 预测大小一致的多肽。我们得出的结论是，天然可溶形式的 CTLA-4 源自 CTLA-4 基因的替代转录物，并且其血浆水平在 ATD 患者群体中升高。
We have recently identified a novel transcript of the CTLA-4 gene that may represent a native soluble form of CTLA-4 (sCTLA-4), To determine whether sCTLA-4 was expressed in humans, we applied a sensitive enzyme immunoassay on serum from patients with autoimmune thyroid disease (ATD), Eleven of 20 patients with ATD had circulating levels of sCTLA-4 ranging from 28 to 78 ng/ml, whereas only 1 of 30 apparently healthy volunteers had a level greater than 4 ng/ml. sCTLA-4 immunoreactivity was inhibited by its binding to B7.1, suggesting that sCTLA-4 is a functional receptor. Immunoprecipitation analysis of serum from patients with ATD revealed a polypeptide consistent with the predicted size of sCTLA-4, We conclude that a native soluble form of CTLA-4 is derived from an alternate transcript of the CTLA-4 gene, and its level in plasma is elevated among a population of patients with ATD.